Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data

Victor H. Gonzalez, Joanna Campbell, Nancy M. Holekamp, Szilárd Kiss, Anat Loewenstein, Albert J. Augustin, Julia Ma, Allen C. Ho, Vaishali Patel, Scott M. Whitcup, Pravin U. Dugel

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose To determine whether early visual acuity response to ranibizumab in diabetic macular edema is associated with long-term outcome. Design Post hoc analysis of randomized controlled trial data. Methods Pooled data from the ranibizumab plus prompt and deferred laser treatment arms of the Diabetic Retinopathy Clinical Research Network's Protocol I study were used to explore the relationship between early (week 12) and late (weeks 52–156) visual acuity response (mean change from baseline in best-corrected visual acuity [CFB BCVA]; categorized improvement [<5, 5–9, or ≥10 Early Treatment Diabetic Retinopathy Study (ETDRS) letters] in BCVA). Results In the analysis population (340 eyes), <5-, 5- to 9-, and ≥10-letter BCVA improvements occurred in 39.7%, 23.2%, and 37.1% of eyes, respectively, at 12 weeks, and 34.2%, 16.5%, and 49.3% of eyes at 156 weeks. Within each early BCVA response category (<5, 5–9, and ≥10 letters of improvement at 12 weeks), mean CFB BCVA at 52–156 weeks varied by <5 letters from that at 12 weeks. CFB BCVA and <5-letter improvement at 12 weeks showed significant positive and negative association, respectively, with CFB BCVA and ≥10-letter improvement at 52 and 156 weeks. Similar relationships were demonstrated in eyes with baseline BCVA <69 letters, and associations remained significant after multivariate adjustment for potential confounders. Conclusions Ranibizumab ± laser therapy resulted in similar rates (∼40%) of suboptimal (<5-letter) and pronounced (≥10-letter) BCVA improvement at 12 weeks. Eyes with suboptimal early BCVA response showed poorer long-term visual outcomes than eyes with pronounced early response (mean improvement 3.0 vs 13.8 letters at 156 weeks).

Original languageEnglish
Pages (from-to)72-79
Number of pages8
JournalAmerican Journal of Ophthalmology
Volume172
DOIs
StatePublished - 1 Dec 2016

Fingerprint

Dive into the research topics of 'Early and Long-Term Responses to Anti–Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Analysis of Protocol I Data'. Together they form a unique fingerprint.

Cite this